CARDIOVASCULAR EVENTS IN SYSTEMIC LUPUS ERYTHEMATOSUS: MECHANISMS FOR THE ACCELERATED DEVELOPMENT OF ATHEROSCLEROSIS, DIAGNOSIS, CORRECTION CAPABILITIES

Atherosclerosis and its complications are the major cause of late mortality among patients with systemic lupus erythematosus (SLE). SLE and coronary heart disease share common pathophysiological mechanisms associated with systemic and chronic inflammation. At the same time, traditional risk factors,...

Full description

Saved in:
Bibliographic Details
Main Authors: A. V. Arshinov, N. Yu. Levshin, I. G. Maslova
Format: Article
Language:Russian
Published: IMA PRESS LLC 2017-07-01
Series:Научно-практическая ревматология
Subjects:
Online Access:https://rsp.mediar-press.net/rsp/article/view/2383
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849688890318782464
author A. V. Arshinov
N. Yu. Levshin
I. G. Maslova
author_facet A. V. Arshinov
N. Yu. Levshin
I. G. Maslova
author_sort A. V. Arshinov
collection DOAJ
description Atherosclerosis and its complications are the major cause of late mortality among patients with systemic lupus erythematosus (SLE). SLE and coronary heart disease share common pathophysiological mechanisms associated with systemic and chronic inflammation. At the same time, traditional risk factors, such as hypertension, elderly age, smoking, hypercholesterolemia, obesity, and male sex, cannot fully explain the mechanism for the accelerated development of atherosclerosis in patients with SLE. Specific risk factors, such as its duration, glucocorticoid use, anti-doublestranded (native) DNA autoantibodies and antiphospholipid antibodies, create conditions for the accelerated development of atherosclerosis in this group of patients.The available facts indicate that a rheumatologist can reduce the risk of cardiovascular disease (CVD), by controlling the activity of SLE. Traditional CVD risk factors should be also modified with smoking cessation, weight loss, and blood pressure control. It is necessary to keep in mind the role of anti-inflammatory therapy, in particular the positive effect of drugs, such as anti-malarial drugs and mycophenolate mofetil, and the adverse prognostic effect of prolonged glucocorticoid use. Further studies should assist in elaborating effective risk scales and specific therapeutic programs for the prevention and treatment of CVD in patients with SLE.
format Article
id doaj-art-bb3513f56daa4d0fa7bb62179401ffd8
institution DOAJ
issn 1995-4484
1995-4492
language Russian
publishDate 2017-07-01
publisher IMA PRESS LLC
record_format Article
series Научно-практическая ревматология
spelling doaj-art-bb3513f56daa4d0fa7bb62179401ffd82025-08-20T03:21:50ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922017-07-0155330431010.14412/1995-4484-2017-304-3102236CARDIOVASCULAR EVENTS IN SYSTEMIC LUPUS ERYTHEMATOSUS: MECHANISMS FOR THE ACCELERATED DEVELOPMENT OF ATHEROSCLEROSIS, DIAGNOSIS, CORRECTION CAPABILITIESA. V. Arshinov0N. Yu. Levshin1I. G. Maslova2Yaroslavl State Medical University, Ministry of Health of Russia, YaroslavlYaroslavl State Medical University, Ministry of Health of Russia, YaroslavlYaroslavl State Medical University, Ministry of Health of Russia, YaroslavlAtherosclerosis and its complications are the major cause of late mortality among patients with systemic lupus erythematosus (SLE). SLE and coronary heart disease share common pathophysiological mechanisms associated with systemic and chronic inflammation. At the same time, traditional risk factors, such as hypertension, elderly age, smoking, hypercholesterolemia, obesity, and male sex, cannot fully explain the mechanism for the accelerated development of atherosclerosis in patients with SLE. Specific risk factors, such as its duration, glucocorticoid use, anti-doublestranded (native) DNA autoantibodies and antiphospholipid antibodies, create conditions for the accelerated development of atherosclerosis in this group of patients.The available facts indicate that a rheumatologist can reduce the risk of cardiovascular disease (CVD), by controlling the activity of SLE. Traditional CVD risk factors should be also modified with smoking cessation, weight loss, and blood pressure control. It is necessary to keep in mind the role of anti-inflammatory therapy, in particular the positive effect of drugs, such as anti-malarial drugs and mycophenolate mofetil, and the adverse prognostic effect of prolonged glucocorticoid use. Further studies should assist in elaborating effective risk scales and specific therapeutic programs for the prevention and treatment of CVD in patients with SLE.https://rsp.mediar-press.net/rsp/article/view/2383systemic lupus erythematosusatherosclerosis, nontraditional cardiovascular risk factorstreatment of cardiovascular events
spellingShingle A. V. Arshinov
N. Yu. Levshin
I. G. Maslova
CARDIOVASCULAR EVENTS IN SYSTEMIC LUPUS ERYTHEMATOSUS: MECHANISMS FOR THE ACCELERATED DEVELOPMENT OF ATHEROSCLEROSIS, DIAGNOSIS, CORRECTION CAPABILITIES
Научно-практическая ревматология
systemic lupus erythematosus
atherosclerosis, nontraditional cardiovascular risk factors
treatment of cardiovascular events
title CARDIOVASCULAR EVENTS IN SYSTEMIC LUPUS ERYTHEMATOSUS: MECHANISMS FOR THE ACCELERATED DEVELOPMENT OF ATHEROSCLEROSIS, DIAGNOSIS, CORRECTION CAPABILITIES
title_full CARDIOVASCULAR EVENTS IN SYSTEMIC LUPUS ERYTHEMATOSUS: MECHANISMS FOR THE ACCELERATED DEVELOPMENT OF ATHEROSCLEROSIS, DIAGNOSIS, CORRECTION CAPABILITIES
title_fullStr CARDIOVASCULAR EVENTS IN SYSTEMIC LUPUS ERYTHEMATOSUS: MECHANISMS FOR THE ACCELERATED DEVELOPMENT OF ATHEROSCLEROSIS, DIAGNOSIS, CORRECTION CAPABILITIES
title_full_unstemmed CARDIOVASCULAR EVENTS IN SYSTEMIC LUPUS ERYTHEMATOSUS: MECHANISMS FOR THE ACCELERATED DEVELOPMENT OF ATHEROSCLEROSIS, DIAGNOSIS, CORRECTION CAPABILITIES
title_short CARDIOVASCULAR EVENTS IN SYSTEMIC LUPUS ERYTHEMATOSUS: MECHANISMS FOR THE ACCELERATED DEVELOPMENT OF ATHEROSCLEROSIS, DIAGNOSIS, CORRECTION CAPABILITIES
title_sort cardiovascular events in systemic lupus erythematosus mechanisms for the accelerated development of atherosclerosis diagnosis correction capabilities
topic systemic lupus erythematosus
atherosclerosis, nontraditional cardiovascular risk factors
treatment of cardiovascular events
url https://rsp.mediar-press.net/rsp/article/view/2383
work_keys_str_mv AT avarshinov cardiovasculareventsinsystemiclupuserythematosusmechanismsfortheaccelerateddevelopmentofatherosclerosisdiagnosiscorrectioncapabilities
AT nyulevshin cardiovasculareventsinsystemiclupuserythematosusmechanismsfortheaccelerateddevelopmentofatherosclerosisdiagnosiscorrectioncapabilities
AT igmaslova cardiovasculareventsinsystemiclupuserythematosusmechanismsfortheaccelerateddevelopmentofatherosclerosisdiagnosiscorrectioncapabilities